vimarsana.com
  1. Home
  2. Live Updates
  3. Initial Coverage - Breaking News

Page 6 - Initial Coverage News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Original-Research: Defence Therapeutics Inc (von GBC AG): BUY

^ Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY Kursziel: 11,02 CAD (7,06 EUR) Kursziel auf Sicht von: 31.

Julien desrosiersCosmin filkerDefence therapeutics incResearch report initial coverageDefence therapeuticsResearch reportInitial coverageCancer vaccinesEinen katalog

Original-Research: Defence Therapeutics Inc (von GBC AG): BUY

Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research

Julien desrosiersCosmin filkerDefence therapeutics incResearch report initial coverageDefence therapeuticsResearch reportInitial coverageCancer vaccinesEinen katalog

Original-Research: Defence Therapeutics Inc (von GBC AG): -

Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research

Julien desrosiersCosmin filkerSebastien plouffeSarkis meterissianSimon beaudoinMoutih rafeiResearch watchlistDefence therapeutics incInnovation centre university of albertaBreast centerResearch commentHead of the tumor site groupDrug developmentDefence therapeuticsInvestment advisorTumor site group

Original-Research: Defence Therapeutics Inc (von GBC AG)

Original-Research: Defence Therapeutics Inc. - von GBC AGEinstufung von GBC AG zu Defence Therapeutics Inc.Unternehmen: Defence Therapeutics Inc.ISIN: CA24463V1013Anlass der Studie: Research CommentEmpfehlung: -Kursziel: -Letzte Ratingänderung: Analyst: Julien Desrosiers, Cosmin FilkerGBC Research Watchlist: Defence.

Julien desrosiersCosmin filkerSebastien plouffeSarkis meterissianSimon beaudoinMoutih rafeiResearch watchlistDefence therapeutics incInnovation centre university of albertaBreast centerResearch comment empfehlungHead of the tumor site groupDrug developmentDefence therapeuticsInvestment advisorTumor site group

Original-Research: Cogia AG (von GBC AG): BUY

Original-Research: Cogia AG - von GBC AG Einstufung von GBC AG zu Cogia AG Unternehmen: Cogia AG ISIN: DE000A3H2226 Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY Kursziel:

Felix hauggMatthias greiffenbergerResearch report initial coverageFraunhofer instituteResearch reportInitial coverageBig dataBig data analyticsFree stateEinen katalog

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.